News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ)'s Codman Neuro Recall Elevated To High Risk Class I


1/23/2014 10:12:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Johnson & Johnson subsidiary Codman Neuro's recall of its Trufill n-BCA liquid embolic system gets labeled as a Class I measure by the FDA. Codman Neuro, a division of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes, said the FDA labeled its Trufill n-BCA liquid embolic system recall as Class I, the federal watchdog agency's highest-risk classification. The Raynham, Mass.-based company develops devices for neurosurgery, neurovascular repair and neuromodulation.

Help employers find you! Check out all the jobs and post your resume.

Read at MassDevice


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES